Document Type
Note
Abstract
Pharmaceutical manufacturers can delay the generic entry for a blockbuster drug. In order to keep the generic system on track, it is critical to expose the various avenues of generic delay. Part I of this Note briefly describes the generic entry process as prescribed by the Hatch-Waxman Act. Part II details four well-known tactics used by brand-name manufacturers to block or delay the entry of generic competition, highlighting how the tactics are successful. Part III concludes by examining the nature of the various problems and arguing that the first step towards ending the different forms of anticompetitive behavior is through increased disclosure requirements.
Recommended Citation
William Ulrich,
The Price of Competition: Analyzing Anticompetitive Tactics in Pharmaceutical Markets During the Hatch-Waxman Era,
4
Notre Dame J. on Emerging Tech.
148
(2023).
Included in
Health Law and Policy Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Science and Technology Law Commons, Social Welfare Commons